Ursolizin (ursodeoxycholic acid) capsules 150 mg. №20

$23.40

Manufacturer: Italy

Ursolizin is indicated in patients with radio-negative, non-calcified gallbladder stones <20 mm in largest diameter for whom facultative cholecystectomy can be performed, including patients at high surgical risk through systemic disease, elderly patients from surgery.
Ursolizin is prescribed to prevent the formation of gallstones in obese patients who plan to lose weight quickly.

Out of stock

Description

Ursolizin (ursodeoxycholic acid) capsules 150 mg. №20

Composition

active substance: ursodeoxycholic acid;

1 capsule contains ursodeoxycholic acid 150 mg or 300 mg;

Excipients: corn starch, magnesium stearate, colloidal anhydrous silica, gelatin, titanium dioxide (E 171).

Dosage form

Capsules.

Main physical and chemical properties: white hard gelatin capsules containing white powder (conglomerates may form during storage).

Pharmacotherapeutic group

Drugs used in diseases of the liver and biliary tract. Means used in biliary pathology.

ATX code A05A A02.

Pharmacological properties

This is a remedy used in diseases of the biliary tract. Ursodeoxycholic acid is a component of human bile. It reduces the saturation of bile with cholesterol by inhibiting its absorption in the intestine, reducing its excretion into bile. This helps dissolve cholesterol calculi (stones). The effect of this drug in cholestatic processes and liver diseases is due to the relative replacement of detergent-like, lipophilic, toxic bile acids with non-toxic, cytoprotective, hydrophilic ursodeoxycholic acid, as well as the ability to improve the secretory capacity of hepatocytes, immunoregulatory processes.

Indications

Ursolizin is indicated:

  •  for dissolution of X-ray-negative cholesterol stones (stones) in the gallbladder, no more than 15 mm in diameter (subject to the conditions of a functioning gallbladder);
  •  with gastritis caused by bile reflux;
  •  for the symptomatic treatment of biliary cirrhosis (primary) in the compensation phase.

Contraindications

Ursolizin should not be used:

  •  with calcified calculi;
  •  with intolerance to the components of the drug;
  •  with obstruction of the biliary tract (bladder duct, common bile duct);
  •  with radiologically confirmed presence of calculi;
  •  with acute inflammation of the gallbladder, biliary tract;
  •  in violation of the contractile function of the gallbladder, frequent biliary colic.

Application during pregnancy and lactation

There is no sufficient data on the use of this medication in pregnant women. In this regard, the use during this period is possible only by the decision of the doctor.
It is not known whether ursodeoxycholic acid penetrates into breast milk, so Ursolizin is not used during breastfeeding or is temporarily discontinued.

Method of administration and dosage

Ursolizin is used orally.

The drug should be used under medical supervision. For patients weighing less than 47 kg or who have difficulty swallowing capsules, it is recommended to use the drug in another dosage form, such as a suspension.

  • To dissolve cholesterol gallstones
    The recommended dose is 10 mg of ursodeoxycholic acid / kg body weight. Capsules should be swallowed whole, washed down with water, once a day at night before bedtime. The capsules should be taken regularly.
    The time required to dissolve gallstones is usually 6-24 months. If the reduction in the size of gallstones is not observed after 12 months of reception, therapy should be discontinued.
    The success of the treatment should be checked every 6 months by ultrasound or X-ray examination. Additional research is needed to verify that calcification of the stones has not occurred over time. If this happens, treatment should be stopped.
  • For the treatment of biliary reflux gastritis
    The dosage of the drug and the duration of treatment is determined by the doctor for each patient individually. Usually you should take 1 capsule a day in the evening before bedtime for 10-14 days.
  • For the symptomatic treatment of primary biliary cirrhosis (PBC)
    The daily dose depends on body weight and is 14 ± 2 mg ursodeoxycholic acid / kg body weight.
    In the first 3 months of treatment, the capsules should be taken by dividing the daily dose into 3 doses during the day. If liver function improves, the daily dose can be taken once a day in the evening.

Body weight (kg) 47-62 – 12-16 mg / kg body weight;

Body weight (kg) 63-78 – 13-16 mg / kg body weight;

Body weight (kg) 79-93 – 13-16 mg / kg body weight;

Body weight (kg) 94 and more – 14-16 mg / kg body weight.

The capsules should be swallowed whole with liquid. It is necessary to adhere to the regularity of reception.

The use of the drug in primary biliary cirrhosis may be unlimited in time.
In patients with primary biliary cirrhosis, clinical symptoms may sometimes worsen at the beginning of          treatment, such as increased itching. If this happens, therapy should be continued by taking 1 capsule per day. After the symptoms of deterioration disappear, the dose should be gradually increased (increasing the daily dose by 1 capsule) until the prescribed dosage is reached.

Children

There are no fundamental restrictions on the use of ursodeoxycholic acid in children, but the capsules should not be used in children weighing less than 47 kg. If the child weighs less than 47 kg and / or has difficulty swallowing, it is recommended to use ursodeoxycholic acid in another dosage form (eg suspension).

Overdose

In cases of overdose, diarrhea may occur. Other manifestations of overdose are unlikely, since the absorption of ursodeoxycholic acid decreases with increasing dose and a large amount of it is excreted in the feces.
With the development of diarrhea, it is recommended to reduce the dose, and with persistent diarrhea, to stop therapy.
Overdose treatment is symptomatic. It is necessary to restore fluid balance, normalize electrolyte levels.

Side effects:

  • digestive disorders: mushy stools, diarrhea, pain in the right hypochondrium, calcification of calculi, decompensation of liver diseases;
  • hypersensitivity reactions: urticaria, skin rash.